Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

104 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Validation of tissue microarray technology in breast carcinoma.
Camp RL, Charette LA, Rimm DL. Camp RL, et al. Lab Invest. 2000 Dec;80(12):1943-9. doi: 10.1038/labinvest.3780204. Lab Invest. 2000. PMID: 11140706
Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.
Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Garcia-Rostan G, et al. Am J Pathol. 2001 Mar;158(3):987-96. doi: 10.1016/s0002-9440(10)64045-x. Am J Pathol. 2001. PMID: 11238046 Free PMC article.
Tissue microarray: a new technology for amplification of tissue resources.
Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Rimm DL, et al. Cancer J. 2001 Jan-Feb;7(1):24-31. Cancer J. 2001. PMID: 11269645 Review.
Amplification of tissue by construction of tissue microarrays.
Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E. Rimm DL, et al. Exp Mol Pathol. 2001 Jun;70(3):255-64. doi: 10.1006/exmp.2001.2363. Exp Mol Pathol. 2001. PMID: 11418004 Review.
Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.
Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Dolled-Filhart M, et al. Clin Cancer Res. 2003 Feb;9(2):594-600. Clin Cancer Res. 2003. PMID: 12576423
104 results
Jump to page
Feedback